CFC phase-out by therapeutic class is inappropriate, Glaxo's Rickard tells advisory committee.
Executive Summary
CFC PHASE-OUT BY THERAPEUTIC CLASS IS INAPPROPRIATE, GLAXO WELLCOME U.S. Medical Affairs Respiratory Director Kathleen Rickard, MD, said at an April 11 FDA Pulmonary-Allergy Drugs Advisory Committee meeting on FDA's proposed chloro-fluorocarbons phase-out process. "The continued availability of individual class products should be a major consideration in light of the proposal that could reduce available medications to two active ingredients per therapeutic class," Rickard said.